Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval

Sponsor
Agenus Inc.
Study ID
NCT06751524
Status
Available

Conditions

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Botensilimab — DRUG
    Administered via an intravenous (IV) infusion of Botensilimab + Balstilimab combination (BOT+BAL).
  • Balstililmab — DRUG
    Administered via an IV infusion of Botensilimab + Balstilimab combination (BOT+BAL).

Study Details

This is an expanded access program (EAP) designed to provide access to Botensilimab and Balstilimab prior to drug registration by the applicable local regulatory agency. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Key Dates

Status verified
May 2026

Central Contacts

  • Requests for expanded access use must be initiated by a treating physician. Physicians should contact:
    +1-781-202-1614
    [email protected]

Related Studies